Selinexor is a novel inhibitor of <scp>DNA</scp> damage response in Merkel cell carcinoma-Reference-Cited by-同舟云学术

Selinexor is a novel inhibitor of DNA damage response in Merkel cell carcinoma

Published:2022-03-16 Issue:7 Volume:47 Page:1354-1357
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:Clin Experimental Derm

Author:

Moore Stephen Andrew¹²^ORCID,Narayanan Deepika¹^ORCID,Simonette Rebecca A.¹,Bartley Brooke Randi¹^ORCID,Doan Hung Quoc³,Rady Peter L.¹,Tyring Stephen K.¹

Affiliation:

1. Department of Dermatology The University of Texas McGovern Medical School Houston TX USA

2. Rice University Houston TX USA

3. Division of Internal Medicine, Department of Dermatology The University of Texas MD Anderson Cancer Center Houston TX USA

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ced.15120

Reference10 articles.

1. Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?

2. Host DNA Damage Response Factors Localize to Merkel Cell Polyomavirus DNA Replication Sites To Support Efficient Viral DNA Replication

3. Merkel Cell Polyomavirus Small T Antigen Induces DNA Damage Response

4. Targeting the expression of T antigens with selinexor (KPT‐330) shows promise for Merkel cell polyomavirus‐positive Merkel cell carcinoma treatment

5. The ‘comeback’ of Selinexor: From toxic to tolerable

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of selinexor on prostaglandin synthesis in virus-positive Merkel cell carcinoma cell lines;Archives of Dermatological Research;2024-06-01

2. Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy;IUBMB Life;2023-08-25

3. Effect of selinexor on lipogenesis in virus-positive Merkel cell carcinoma cell lines;Clinical and Experimental Dermatology;2023-05-16

4. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review;Journal of Cancer Research and Clinical Oncology;2022-08-08